# XBiotech Inc.: Form 10-Q for the period ended Mar 31, 2019

- Company: [XBiotech Inc.](/companies/xbit.md) (CIK 1626878)
- Form: 10-Q
- Filed: 2019-05-09
- Accepted by EDGAR: May 9, 2019, 14:37 ET
- Period: 2019-03-31
- Accession: 0001171843-19-003199
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1626878/000117184319003199/f10q_050919p.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1626878/000117184319003199/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2019-03-31.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Research and development | 3 months, 2019-01-01 to 2019-03-31 | $4.5m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months, 2019-01-01 to 2019-03-31 | −$5.8m | us-gaap:OperatingIncomeLoss |
| Net income | 3 months, 2019-01-01 to 2019-03-31 | −$5.9m | us-gaap:NetIncomeLoss |
| Operating cash flow | 3 months, 2019-01-01 to 2019-03-31 | −$4.7m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 3 months, 2019-01-01 to 2019-03-31 | $6.0k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | at 2019-03-31 | $12.0m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2019-03-31 | $13.0m | us-gaap:AssetsCurrent |
| Total assets | at 2019-03-31 | $39.8m | us-gaap:Assets |
| Current liabilities | at 2019-03-31 | $2.8m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2019-03-31 | $2.8m | us-gaap:Liabilities |
| Shareholders' equity | at 2019-03-31 | $37.0m | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 13,860 characters.

### MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

### Overview

XBiotech Inc. (“XBiotech” or the “Company) is a pre-market biopharmaceutical company engaged in discovering and developing True Human™ monoclonal antibodies for treating a variety of diseases. True Human™ monoclonal antibodies are those which occur naturally in human beings—as opposed to being derived from animal immunization or otherwise engineered. We believe that naturally occurring monoclonal antibodies have the potential to be safer and more effective than their non-naturally occurring counterparts. XBiotech is focused on developing its True Human™ pipeline and manufacturing system.

We have never been profitable and, as of March 31, 2019, we had an accumulated deficit of $243.6 million. We had net losses of $5.8 million and $4.1 million for the three months ended March 31, 2019 and 2018, respectively. We expect to incur significant and increasing operating losses for the foreseeable future as we advance our drug candidates from discovery through preclinical testing and clinical trials and seek regulatory approval and eventual commercialization. In addition to these increasing research and development expenses, we expect general and administrative costs to increase as we add personnel and continue to operate as a public company. We will need to generate significant revenues to achieve profitability, and we may never do so. As of March 31, 2019, we had 56 employees.

### Recent Events:

The Company has recently completed two open label, multi center phase 2 clinical studies evaluating bermekimab as a treatment for atopic dermatitis and hidradenitis suppurativa. The Company announced positive findings from these studies, both of which were presented at the American Academy of Dermatology’s Annual Meeting in March 2019. XBiotech plans to continue its pursuit of the development of its clinical pipeline along with research and development efforts to enable selection of drug candidates and research projects for further development in response to their preclinical and clinical success and commercial potential.

### Risks

The Company continues to be subject to a number of risks common to companies in similar stages of development. Principal among these risks are the uncertainties of technological innovations, dependence on key individuals, development of the same or similar technological innovations by the Company’s competitors and protection of proprietary technology. The Company’s ability to fund its planned clinical operations, including completion of its planned clinical trials, is expected to depend on the amount and timing of cash receipts from future collaboration or product sales and/or financing transactions. The Company believes that its cash and cash equivalents of $12.0 million at March 31, 2019 will enable the Company to achieve some key inflection points, including clinical studies in certain indication(s), as well as on-going R&D efforts for the Company’s pre-clinical pipeline. Based on our research and development plans and our timing expectations related to the progress of our programs, we expect that our cash and cash equivalents as of March 31, 2019 will enable us to fund our operating expenses and capital expenditure requirements through March 31, 2020. We have based this estimate on assumptions that may prove to be inaccurate, and we could utilize our available capital resources sooner than we currently expect.

### Revenues

To date, we have not generated any revenue. Our ability to generate revenue and become profitable depends on our ability to successfully commercialize our lead product candidate, bermekimab, or any other product candidate we may advance in the future.

### Research and Development Expenses

Research and development expense consists of expenses incurred in connection with identifying and developing our drug candidates. These expenses consist primarily of salaries and related expenses, stock-based compensation, the purchase of equipment, laboratory and manufacturing supplies, facility costs, costs for preclinical and clinical research, development of quality control systems, quality assurance programs and manufacturing processes. We charge all research and development expenses to operations as incurred.

Clinical development timelines, likelihood of success and total costs vary widely. We do not currently track our internal research and development costs or our personnel and related costs on an individual drug candidate basis. We use our research and development resources, including employees and our drug discovery technology, across multiple drug development programs. As a result, we cannot state precisely the costs incurred for each of our research and development programs or our clinical and preclinical drug candidates. From inception through March 31, 2019, we have recorded total research and development expenses, including share-based compensation, of $190.2 million. Our total research and development expenses for the three months ended March 31, 2019 and 2018 were $4.5 million and $3.0 million, respectively. Share-based compensation accounted for $295 thousand and $100 thousand for the three months ended March 31, 2019 and 2018, respectively.

Research and development expenses, as a percentage of total operating expenses for the three months ended March 31, 2019 and 2018 were 78% and 72%, respectively. The percentages, excluding stock-based compensation, for the three months ended March 31, 2019 and 2018, were 81% and 72%, respectively.

The clinical development costs may further increase going forward with potentially more advanced studies in the future as we evaluate our clinical data and pipeline.

Based on the results of our preclinical studies, we anticipate that we will select drug candidates and research projects for further development on an ongoing basis in response to their preclinical and clinical success and commercial potential. For research and development candidates in early stages of development, it is premature to estimate when material net cash inflows from these projects might occur.

### General and Administrative Expenses

General and administrative expense consists primarily of salaries and related expenses for personnel in administrative, finance, business development and human resource functions, as well as the legal costs of pursuing patent protection of our intellectual property and patent filing and maintenance expenses, stock–based compensation, and professional fees for legal services. Our total general and administration expenses for the three months ended March 31, 2019 and 2018 were $1.3 million and $1.2 million, respectively. Share-based compensation accounted for $275 thousand and $22 thousand for the three months ended March 31, 2019 and 2018, respectively.

General and administrative expense, as a percentage of total operating expenses for the three months ended March 31, 2019 and 2018 were 22% and 28%, respectively. The percentages, excluding stock-based compensation, for the three months ended March 31, 2019 and 2018, were 19% and 28%, respectively.

### Critical Accounting Policies

The preparation of financial statements in conformity with generally accepted accounting principles requires us to make judgments, estimates and assumptions in the preparation of our consolidated financial statements and accompanying notes. Actual results could differ from those estimates. We believe there have been no significant changes in our critical accounting policies as discussed in our Annual Report on Form 10-K for the year ended December 31, 2018.

### Results of Operations

### Revenue

We did not record any revenue during the three months ended March 31, 2019 and 2018.

### Expenses

#### Research and Development

Research and Development costs are summarized as follows (in thousands):

|  | Three Months Ended March 31, 2019 | 2018 | Increase (Decrease) | % Increase (Decrease) |
| --- | ---: | ---: | ---: | ---: |
| Salaries and related expenses | $1,166 | $1,051 | $115 | 11% |
| Laboratory and manufacturing supplies | 1,242 | 213 | 1,029 | 483% |
| Clinical trials and sponsored research | 256 | 8 | 248 | 3100% |
| Stock-based compensation | 295 | 88 | 207 | 235% |
| Other | 1,568 | 1,633 | (65) | -4% |
| Total | $4,527 | $2,993 | $1,534 | 51% |

We do not currently track our internal research and development costs or our personnel and related costs on an individual drug candidate basis. We use our research and development resources, including employees and our drug discovery technology, across multiple drug development programs. As a result, we cannot state precisely the costs incurred for each of our research and development programs or our clinical and preclinical drug candidates.

Research and development expenses increased $1.5 million to $4.5 million for the three months ended March 31, 2019, compared to $3.0 million for the three months ended March 31, 2018. The increase was mainly due to a $1.0 million increase of laboratory and manufacturing supplies, related to the clinical drug manufacturing. In addition, there was an increase in clinical trials and sponsored research due to the active trials started in 2018. Stock-based compensation also increased due to the new grants to employees in 2018 and 2019.

#### General and Administrative

General and administrative costs are summarized as follows (in thousands):

|  | Three Months Ended March 31, 2019 | 2018 | Increase (Decrease) | % Increase (Decrease) |
| --- | ---: | ---: | ---: | ---: |
| Salaries and related expenses | $254 | $324 | $(70) | -22% |
| Patent filing expense | 199 | 181 | 18 | 10% |
| Stock-based compensation | 275 | 22 | 253 | 1150% |
| Professional fees | 184 | 207 | (23) | -11% |
| Other | 366 | 423 | (57) | -13% |
| Total | $1,278 | $1,157 | $121 | 10% |

General and administrative expense increased $0.1 million to $1.3 million for the three months ended March 31, 2019, compared to $1.2 million for the three months ended March 31, 2018. The increase was primarily related to stock–based compensation expenses of $0.3 million, due to the new grants to employees in 2018 and 2019. We had offsetting decreases in Salaries and related expense and facility allocation expense in other expense, due to one employee transferred from general and administrative to research and development.

### Other income (loss)

The following table summarizes other income (loss) (in thousands):

|  | Three Months Ended March 31, 2019 | 2018 |
| --- | ---: | ---: |
| Interest income | $78 | $64 |
| Other income | 9 | - |
| Foreign exchange gain (loss) | (146) | 17 |
| Total | $(59) | $81 |

The interest income for the three months ended March 31, 2019 and 2018 was mainly from the interest generated from the Company’s Canadian bank account. Foreign exchange gain and loss was mainly due to the fluctuation between US dollar and Euro in the three months ended March 31, 2019 compared to the three months ended March 31, 2018.

### Liquidity and Capital Resources

Our cash requirements could change materially as a result of the progress of our research and development and clinical programs, licensing activities, acquisitions, divestitures or other corporate developments.

Since our inception on March 22, 2005 through March 31, 2019, we have funded our operations principally through public offerings and the private placement of equity securities, which have provided aggregate cash proceeds of approximately $258.1 million. The following table summarizes our sources and uses of cash (in thousands):

| Net cash (used in) provided by: | Three Months Ended March 31, 2019 | 2018 |
| --- | ---: | ---: |
| Operating activities | $(4,677) | $(3,526) |
| Investing activities | (6) | (34) |
| Financing activities | 741 | 201 |
| Effect of foreign exchange rate on cash and cash equivalents | 138 | 7 |
| Net change in cash and cash equivalents | $(3,804) | $(3,352) |

During the three months ended March 31, 2019 and 2018, our operating activities used net cash of $4.7 million and $3.5 million, respectively. The use of net cash in each of these periods primarily resulted from our net losses. The increase in net loss from operations for the three months ended March 31, 2019 as compared to the three months ended March 31, 2018 was mainly due to the increase in laboratory and manufacturing supplies.

During the three months ended March 31, 2019 and 2018, our investing activities used net cash of $6 thousand and $34 thousand, respectively. The use of cash was for the purchase of new research and development equipment.

During the three months ended March 31, 2019 and 2018, our financing activities provided net cash proceeds of $0.7 million and $0.2 million, respectively. During the three months ended March 31, 2019, employees exercised stock options to purchase a total of 190 thousand shares of our common stock for approximately $0.5 million in net proceeds. In this period, the Company also collected $0.2 million of its subscription receivable balance. During the three months ended March 31, 2018, employees exercised stock options to purchase a total of 81 thousand shares of our common stock for approximately $0.2 million in net proceeds.

We expect to continue to incur substantial operating losses in the future. We will not receive any product revenue until a drug candidate has been approved by the FDA, EMA or similar regulatory agencies in other countries and successfully commercialized. As of March 31, 2019, our principal sources of liquidity were our cash and cash equivalents, which totaled approximately $12.0 million.

### Off-Balance Sheet Arrangements

Since inception, we have not engaged in any off-balance sheet activities, including the use of structured finance, special purpose entities or variable interest entities.

## Market risk

As filed, 308 characters.

The Company is not currently exposed to material market risk arising from financial instruments, changes in interest rates or commodity prices, or fluctuations in foreign currencies. The Company has no need to hedge against any of the foregoing risks and therefore currently engages in no hedging activities.

## Controls and procedures

As filed, 1,804 characters.

### Management's Evaluation of our Disclosure Controls and Procedures

As of the end of the period covered by this Quarterly Report on Form 10-Q, an evaluation was carried out by the Company’s management, with the participation of the Chief Executive Officer and Principal Financial Officer, of the effectiveness of the Company’s disclosure controls and procedures, as defined in Rule 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934. Based on such evaluation, the Chief Executive Officer and Principal Financial Officer concluded that the Company’s disclosure controls and procedures are effective to ensure that information required to be disclosed in the reports the Company files or furnishes under the Securities Exchange Act of 1934 is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and regulations, and are operating in an effective manner.

### Changes in Internal Control Over Financial Reporting

There was no change in our internal control over financial reporting that occurred during the first quarter of the year ended December 31, 2019 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

### Limitations on Effectiveness of Controls and Procedures

In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints and that management is required to apply judgment in evaluating the benefits of possible controls and procedures relative to their costs.

Filed May 9, 2019.
Source: SEC EDGAR, the filing index for accession 0001171843-19-003199. Last ingested by Listed: Nov 14, 2026, 18:14 ET. No prices; not investment advice.
